{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T02:28:16Z","timestamp":1744079296366},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,16]]},"DOI":"10.7759\/cureus.45334","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T07:39:43Z","timestamp":1694849983000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Toxic Epidermal Necrolysis Caused by Lamotrigine Combined With Valproic Acid and Literature Review"],"prefix":"10.7759","author":[{"given":"Haifeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2012.662253","article-title":"A lamotrigine induced toxic epidermal necrolysis in a child","volume":"32","author":"Calka O","year":"2013","unstructured":"Calka O, Karadag AS, Bilgili SG, Bulut G, Altun F, Burakgazi AZ. A lamotrigine induced toxic epidermal necrolysis in a child. J Toxicol Cutaneous Ocular Toxicol. 2013, 32:86-8. 10.3109\/15569527.2012.662253","journal-title":"J Toxicol Cutaneous Ocular Toxicol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16626","article-title":"Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of a Japanese pharmacovigilance database","volume":"61","author":"Noguchi Y","year":"2020","unstructured":"Noguchi Y, Takaoka M, Hayashi T, Tachi T, Teramachi H. Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of a Japanese pharmacovigilance database. Epilepsia. 2020, 61:1979-89. 10.1111\/epi.16626","journal-title":"Epilepsia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2015.01.016","article-title":"Lamotrigine-induced severe cutaneous adverse reaction: update data from 1999-2014","volume":"22","author":"Wang XQ","year":"2015","unstructured":"Wang XQ, Lv B, Wang HF, et al.. Lamotrigine-induced severe cutaneous adverse reaction: update data from 1999-2014. J Clin Neurosci. 2015, 22:1005-11. 10.1016\/j.jocn.2015.01.016","journal-title":"J Clin Neurosci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s6515","article-title":"Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients","volume":"6","author":"B\u0142aszczyk B","year":"2010","unstructured":"B\u0142aszczyk B, Czuczwar SJ. Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients. Neuropsychiatr Dis Treatment. 2010, 6:145-50. 10.2147\/ndt.s6515","journal-title":"Neuropsychiatr Dis Treatment"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007783.pub2","article-title":"Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures","volume":"12","author":"Tjia-Leong E","year":"2010","unstructured":"Tjia-Leong E, Leong K, Marson AG. Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. Cochrane Database Syst Rev. 2010, 12:007783. 10.1002\/14651858.CD007783.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0394","article-title":"Successful re-introduction of lamotrigine after initial rash","volume":"9","author":"Besag FM","year":"2000","unstructured":"Besag FM, Ng GY, Pool F. Successful re-introduction of lamotrigine after initial rash. Seizure. 2000, 9:282-6. 10.1053\/seiz.2000.0394","journal-title":"Seizure"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s3343","article-title":"Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release","volume":"4","author":"Mary-Ann W","year":"2008","unstructured":"Mary-Ann W. Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release. Therapeut Clin Risk Manag. 2008, 4:1035-46. 10.2147\/tcrm.s3343","journal-title":"Therapeut Clin Risk Manag"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2004.00410.x","article-title":"New medication treatment options for bipolar","volume":"422","author":"Ketter TA","year":"2004","unstructured":"Ketter TA, Wang PW, Nowakowska C, Marsh WK. New medication treatment options for bipolar. Acta Psychiatr Scandinavica. 2004, 422:18-33. 10.1111\/j.1600-0447.2004.00410.x","journal-title":"Acta Psychiatr Scandinavica"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14411","article-title":"Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies","volume":"58","author":"Rashid M","year":"2019","unstructured":"Rashid M, Kashyap A, Undela K. Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. Int J Dermatol. 2019, 58:1014-22. 10.1111\/ijd.14411","journal-title":"Int J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1535759719835672","article-title":"Making rash decisions in epilepsy: evaluating hypersensitivity reactions to anti-seizure medications","volume":"19","author":"Bermeo-Ovalle A","year":"2019","unstructured":"Bermeo-Ovalle A. Making rash decisions in epilepsy: evaluating hypersensitivity reactions to anti-seizure medications. Nature Rev Cancer. 2019, 19:96-8. 10.1177\/1535759719835672","journal-title":"Nature Rev Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2.6.1009","article-title":"Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy","volume":"2","author":"Biton V","year":"2006","unstructured":"Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol. 2006, 2:1009-18. 10.1517\/17425255.2.6.1009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01866.x","article-title":"Lamotrigine-valproic acid combination therapy for medically refractory epilepsy","volume":"50","author":"Moeller JJ","year":"2010","unstructured":"Moeller JJ, Rahey SR, Sadler RM. Lamotrigine-valproic acid combination therapy for medically refractory epilepsy. Epilepsia. 2010, 50:475-9. 10.1111\/j.1528-1167.2008.01866.x","journal-title":"Epilepsia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2005.00381.x","article-title":"Lamotrigine-induced rash--worth a rechallenge","volume":"111","author":"P-Codrea S","year":"2005","unstructured":"P-Codrea S, Sidenius P, Dam M. Lamotrigine-induced rash--worth a rechallenge. Acta Neurologica Scandinavica. 2005, 111:191-4. 10.1111\/j.1600-0404.2005.00381.x","journal-title":"Acta Neurologica Scandinavica"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.06.024","article-title":"Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis","volume":"60","author":"Deng Y","year":"2018","unstructured":"Deng Y, Li S, Zhang L, Jin H, Zou X. Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis. Seizure. 2018, 60:163-71. 10.1016\/j.seizure.2018.06.024","journal-title":"Seizure"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-011-0869-9","article-title":"Vulnerability of an epileptic case to psychosis: sodium valproate with lamotrigine, forced normalization, postictal psychosis or all?","volume":"33","author":"Turan AB","year":"2012","unstructured":"Turan AB, Seferoglu M, Taskapilioglu O, Bora I. Vulnerability of an epileptic case to psychosis: sodium valproate with lamotrigine, forced normalization, postictal psychosis or all?. Neurol Sci. 2012, 33:1161-3. 10.1007\/s10072-011-0869-9","journal-title":"Neurol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14598","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap in pediatric patients with a focus on newer antiepileptic drugs: a 25-year retrospective study at a single tertiary care center","volume":"38","author":"Gleghorn KL","year":"2021","unstructured":"Gleghorn KL, Voigt C, Kelly B. Toxic epidermal necrolysis and Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap in pediatric patients with a focus on newer antiepileptic drugs: a 25-year retrospective study at a single tertiary care center. Pediatr Dermatol. 2021, 38:812-8. 10.1111\/pde.14598","journal-title":"Pediatr Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1016-3190(09)60031-8","article-title":"Toxic epidermal necrolysis due to lamotrigine monotherapy for bipolar disorder","volume":"21","author":"Tseng HW","year":"2009","unstructured":"Tseng HW, Chang CH. Toxic epidermal necrolysis due to lamotrigine monotherapy for bipolar disorder. Tzu Chi Med J. 2009, 21:165-8. 10.1016\/S1016-3190(09)60031-8","journal-title":"Tzu Chi Med J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Therapeut. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Therapeut"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000156354.20227.F0","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics","volume":"64","author":"Mockenhaupt M","year":"2005","unstructured":"Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005, 64:1134-8. 10.1212\/01.WNL.0000156354.20227.F0","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2021.102616","article-title":"Carbamazepine induced toxic epidermal necrolysis and Stevens-Johnson syndrome overlapping during pregnancy in a South-East Asian patient: a case report","volume":"68","author":"Shrestha O","year":"2021","unstructured":"Shrestha O, Pant P, Devkota N, Gurung D, Shrestha DB. Carbamazepine induced toxic epidermal necrolysis and Stevens-Johnson syndrome overlapping during pregnancy in a South-East Asian patient: a case report. Ann Med Surg (Lond). 2021, 68:102616. 10.1016\/j.amsu.2021.102616","journal-title":"Ann Med Surg (Lond)"},{"key":"ref21","article-title":"Fatal toxic epidermal necrolysis related to lamotrigine administration","volume":"18","author":"Page RL 2nd","year":"2012","unstructured":"Page RL 2nd, O'Neil MG, Yarbrough DR 3rd, Conradi S. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy. 2012, 18:392-8.","journal-title":"Pharmacotherapy"},{"key":"ref22","article-title":"A case of lamotrigine combined with sodium valproate causing herpetic epidermolysis bullosa drug rash (Chinese)","volume":"1","author":"Zeng L","year":"2019","unstructured":"Zeng L. A case of lamotrigine combined with sodium valproate causing herpetic epidermolysis bullosa drug rash (Chinese). Central South Pharmacy. 2019, 1:156-7.","journal-title":"Central South Pharmacy"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2014.57.3.153","article-title":"Toxic epidermal necrolysis induced by lamotrigine treatment in a child","volume":"57","author":"Yi Y","year":"2014","unstructured":"Yi Y, Lee JH, Suh ES. Toxic epidermal necrolysis induced by lamotrigine treatment in a child. Korean J Pediatr. 2014, 57:153-6. 10.3345\/kjp.2014.57.3.153","journal-title":"Korean J Pediatr"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.883121","article-title":"Scoring assessments in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Dobry AS","year":"2022","unstructured":"Dobry AS, Himed S, Waters M, Kaffenberger BH. Scoring assessments in Stevens-Johnson syndrome and toxic epidermal necrolysis. Front Med (Lausanne). 2022, 9:883121. 10.3389\/fmed.2022.883121","journal-title":"Front Med (Lausanne)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18746","article-title":"The psychological impact of Stevens-Johnson syndrome and toxic epidermal necrolysis on patients\u2019 lives: a critically appraised topic","volume":"183","author":"O'Reilly P","year":"2020","unstructured":"O'Reilly P, Kennedy C, Meskell P, et al.. The psychological impact of Stevens-Johnson syndrome and toxic epidermal necrolysis on patients\u2019 lives: a critically appraised topic. Br J Dermatol. 2020, 183:452-61. 10.1111\/bjd.18746","journal-title":"Br J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14799","article-title":"Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"175","author":"Dodiuk-Gad RP","year":"2016","unstructured":"Dodiuk-Gad RP, Olteanu C, Feinstein A, et al.. Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2016, 175:422-4. 10.1111\/bjd.14799","journal-title":"Br J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17267","article-title":"Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients","volume":"180","author":"Hefez L","year":"2019","unstructured":"Hefez L, Zaghbib K, Sbidian E, et al.. Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. Br J Dermatol. 2019, 180:1206-13. 10.1111\/bjd.17267","journal-title":"Br J Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19893","article-title":"Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi\u2010based consensus","volume":"185","author":"Br\u00fcggen MC","year":"2021","unstructured":"Br\u00fcggen MC, Le ST, Walsh S, et al.. Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi\u2010based consensus. Br J Dermatol. 2021, 185:616-26. 10.1111\/bjd.19893","journal-title":"Br J Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang CW","year":"2018","unstructured":"Wang CW, Yang LY, Chen CB, et al.. Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018, 128:985-96. 10.1172\/JCI93349","journal-title":"J Clin Invest"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13379","article-title":"A retrospective analysis of Stevens-Johnson syndrome\/toxic epidermal necrolysis treated with corticosteroids","volume":"55","author":"Liu W","year":"2016","unstructured":"Liu W, Nie X, Zhang L. A retrospective analysis of Stevens-Johnson syndrome\/toxic epidermal necrolysis treated with corticosteroids. Intl J Dermatol. 2016, 55:1408-13. 10.1111\/ijd.13379","journal-title":"Intl J Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.11.004","article-title":"Mortality and risk factors on admission in toxic epidermal necrolysis: a cohort study of 59 patients","volume":"70","author":"Watanabe T","year":"2021","unstructured":"Watanabe T, Go H, Saigusa Y, et al.. Mortality and risk factors on admission in toxic epidermal necrolysis: a cohort study of 59 patients. Allergol Int. 2021, 70:229-34. 10.1016\/j.alit.2020.11.004","journal-title":"Allergol Int"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.12.040","article-title":"Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset","volume":"147","author":"Araki Y","year":"2009","unstructured":"Araki Y, Sotozono C, Inatomi T, et al.. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol. 2009, 147:1004-11. 10.1016\/j.ajo.2008.12.040","journal-title":"Am J Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/186841-a-case-of-toxic-epidermal-necrolysis-caused-by-lamotrigine-combined-with-valproic-acid-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:59Z","timestamp":1707509099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/186841-a-case-of-toxic-epidermal-necrolysis-caused-by-lamotrigine-combined-with-valproic-acid-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,16]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.45334","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,16]]}}}